ropeginterferon sold brand name besremi medication used treat polycythemia given common side effects include low levels white blood cells platelets blood components help blood clot muscle joint pain tiredness flulike symptoms increased blood levels gammaglutamyl transferase sign liver ropeginterferon cause liver enzyme elevations low levels white blood cells low levels platelets joint pain fatigue itching upper airway infection muscle pain flulike side effects may also include urinary tract infection depression transient ischemic attacks strokelike approved medical use european union february united states november ropeginterferon first medication approved us food drug administration fda treat polycythemia vera people take regardless treatment history first interferon therapy specifically approved polycythemia fda considers firstinclass european union ropeginterferon indicated monotherapy adults treatment polycythemia vera without symptomatic united states indicated treatment polycythemia effectiveness safety ropeginterferon evaluated multicenter singlearm trial lasted trial adults polycythemia vera received ropeginterferon average five effectiveness ropeginterferon assessed looking many participants achieved complete hematological response meant participants red blood cell volume less without recent phlebotomy normal white cell counts platelet counts normal spleen size blood overall participants complete hematological participants received highest administered dose tolerated every two weeks starting dose lower participants transitioning trial conducted six sites exclusively safety ropeginterferon based primarily findings efficacy study two additional studies served supportive safety therefore number participants representing efficacy findings may differ number participants representing safety findings due different pools study participants analyzed efficacy us food drug administration fda granted application ropeginterferon orphan drug granted approval besremi pharmaessentia